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ABSTRACT 
Introduction 
In Western countries about 25% of prostate cancer (PCa) are high risk tumors at presentation and its 
treatment is still a matter of debate among urologists. When the surgical treatment is chosen the 
proposal of a mini-invasive approach in still a dilemma due to the lack of data in literature. The aim 
of this study is to evaluate feasibility and safety of laparoscopic radical prostatectomy for high-risk 
prostate cancer. 
Material and methods 
The study included 1114 patients with high-riskPCa submitted to LRP between 1998 and 2014. High-
risk patients were defined according to D’Amico classification. We collected functional and 
oncological long terms outcomes and evaluated with univariate and multivariate analyses the role of 
predictive factors for survival and biochemical recurrence (BR). 
Results 
Mean age at the treatment was 62 ± 8 years; mean follow-up was 74 ± 50 months. 
We obtained an OS at a mean follow-up of 74 months of 96.6% (1076 patients) and a DFS of 66.2% 
(737 patients). Age (P= 0.0006), pT (P< 0.0001), pN (P= 0.0018) and surgical margins (P= 0.0076) 
resulted as independent predictors for BR in multivariate analysis. pN (P=0.0025) and Gs (P= 0.0003) 
are independent predictors for OS and CSS in a univariate analysis; just the Gs results significant in 
the multivariate model. 
Conslusion 
According to our encouraging data about oncological and functional outcomes we believe that radical 
prostatectomy represents an effective treatment for patients with high-risk prostate cancer and that 
laparoscopy is a safe approach offering a mini-invasive alternative to open surgery. 
INTRODUCTION 
Despite the introduction of aggressive screening policies in Western countries, about 25% of prostate 
cancers (PCa) are high risk tumors at presentation, [1] according to the D’Amico classification ( stage 
> cT2c and/or PSA > 20 ng/ml and/or Gleason score > 7) [1, 2, 3, 4, 5]. The management of patients 
is complex, since no randomized studies have directly compared the oncological efficacy of surgery, 
radiation therapy and hormonal therapy. [6]. Moreover, when the surgical approach is chosen, 
surgeons have to face another dilemma: is a mininvasive technique such as laparoscopy or robotic 
surgery comparable to traditional open surgery? [7,8,9].  
Laparoscopic radical prostatectomy (LRP) was introduced in the late nineties, but to date only few 
series have shown long-term oncological results of this surgical approach and, moreover, this 
information is lacking especially in patients with high-risk disease. The importance of pure 
laparoscopic procedures is nowadays to underline in literature in order to encourage the use of 
mininvasive procedures in hospital that cannot afford a robot. 
The aim of our study is to evaluate the feasibility and safety of laparoscopic radical prostatectomy in 
terms of intra- and postoperative complications and long term oncological and functional results.  
 MATERIAL AND METHODS 
  
Patient population 
The study included 1114 consecutive patients with high-riskPCa who underwent LRP between May 
1998 and May 2014 in three European Institutions: Henri Mondor University Hospital, Creteil, France 
(428 patients),  SLK Clinic, Heilbronn, Germany (421 patients) and L. Sacco Hospital, Milan, Italy 
(265 patients). High-risk patients were defined according to D’Amico classification: PSA > 20 ng/ml 
and/or Gleason Score ≥ 8 and/or clinical stage > T2c.  
PSA value was always measured before the prostate biopsy. Clinical stage was assigned before 
surgery. Pathologic grading was assessed according to the Gleason system and clinical stage was 
assigned according to the 2002 TNM system [1]. Patients with clinical souspicious of metastatic 
disease were staged with computed tomography (CT) or magnetic resonance (MRI). Bone scan was 
performed according to the EAU guidelines [1].  
Surgical procedure 
All the procedures were performed transperitoneally by expert surgeons who already accomplished 
their learning curve in laparoscopic radical prostatectomy. 
Lymphadenectomy was performed according to the EAU guidelines indications at the moment of 
surgery; in most recent cases extended pelvic limphnode dissection (ePLND) was performed if the 
estimated risk for positive LNs exceeded 5% [1]. 
Data on limphadenectomy are available for 1022 patients (91.7%) due to the retrospective nature of 
the study; most of the pNx patients underwent surgery in the late 90’s when guidelines were still 
evolving about thisprocedure. Lymphadenectomy is performed before or after the prostatectomy 
depending on surgeon habits. If performed after it, lymphadenectomy is always performed before the 
vescico-urethral anastomosis in order to allow a better mobilization of the bladder without damaging 
the anastomosis. We always use a transperitoneal approach to minimize the risk of postoperative 
lymphocele formation. 
Tamplates for standard dissection was the same in all the centers including obturator and external 
iliac nodes. 
Due to the retrospective nature of the study and the variable definition of ePLND in literature the 
exact borders of the dissection is not always standardized in all the centers; all the procedures included 
obturator, external iliac and internal iliac nodes but not clear data are available about presacral, 
common iliac and presciatic nodes. 
  
  
Post-operative evaluation 
The Clavien-Dindo complications grading system was used to evaluate intra- and perioperative 
complications. Postoperative follow-up included digital rectal examination (DRE) and serum PSA 
and was scheduled according to the scheme proposed by EAU PCa guidelines [1]. A telephonic 
update was realized in September 2014 for all patients. Biochemical recurrence (BCR) was defined 
as two consecutive PSA values > 0.2 ng/ml. 
Overall Survival (OS) was defined as the number of alive patients at last follow-up. Cancer Specific 
Survival (CSS) was defined as the number of patients alive after excluding deaths for other causes. 
Disease Free Survival (DFS) was defined as no evidence of BCR at last follow-up.  
Urinary incontinence was evaluated in all patients and continence was defined as the use of 0 pads. 
We didn’t evaluate the potency due to the risk characteristics of our population that exclude a nerve 
sparing approach according to the EAU guidelines; this decision was in 1998 and is still adherent to 
the guidelines where no specific recommendations for high risk tumor is made [1]. 
  
Statistical analysis  
Categorical variables are reported as count (percentage), continuous variables are reported as mean 
(± standard deviation) or median (range), as appropriate. 
Kaplan-Meier analyses were used for the estimation of survival curves, considering BCR, cancer-
specific and all cause mortality  as the events of interest respectively. The log-rank test was used for 
comparison of survival curves between groups of patients.  
Subsequently, univariate and multivariate Cox regression analyses were performed to establish the 
predictors of outcomes. Covariates were age, preoperative PSA, pathological Gleason score, surgical 
margins status, the use of lymphadenectomy, pT and pN. Only those predictors which resulted 
significant in univariate analysis were introduced in the multivariate model. Thereafter, a backward 
elimination procedure was used to find the optimal predictive models. This set of analyses was 
performed for both BCR and cancer-specific mortality. For all the fitted Cox models, the proportional 
hazard assumption was checked. Hazard ratios (HR), with their 95% confidence intervals (CI), were 
derived from the Cox models. 
P values < 0.05, two sided, were considered statistically significant. All the statistical analyses were 
performed with SAS statistical software (release 9.4; SAS Institute Inc., Cary, NC). 
RESULTS 
Patients characteristics, preoperative PSA, clinical stage and bioptic Gleason score are reported in 
Table 1. 
  
Complications 
Table 2 reports all the complications classified according to Clavien Dindo and respective treatments 
[7]. 
Overall 180 patients (16.2%) presented a total of 186 complications. Blood transfusions represented 
the most common postoperative complication, a total of 132 cases (11.8%). Excluding transfusions, 
number of patients with perioperative complications decreases to 54 patients (4.8%). 
The 11 patients presenting symptomatic lymphocele underwent percutaneous drainage.  
Ten patients presented urethral stenosis at different point of follow-up; 6 of them underwent adjuvant 
radiotherapy. 
The overall complication rates were similar in patients undergoing e-PLND, st-PLND, and noPLND 
(15.8% vs.17.2% vs. 16.1. P = 0.412). 
  
Oncological and functional outcomes 
Mean follow-up time was 74 ± 50 months. 
In Table 2 are reported pathological results after LRP. There were 296 patients (26.6%) with pT2 
tumor, 769 (69%) with pT3 tumor including 348 (31.2%) cases of seminal vescicle invasion (pT3b); 
pT4 stage is reported in 49 cases (4.4%). 118 patients (10.6%) presented positive nodes and 383 
(34.4%) positive surgical margins. Most of the tumors (61.6%) resulted with a Gleason score ≤ 7. We 
obtained an OS at a mean follow-up of 74 months of 96.6% (1076 patients) and a DFS of 66.2% (737 
patients). 
The mean (SD) overall lymph node yield was 18.5 (5.7). 
781 patients (76.4%) underwent ePLND with a node yield of 19.1; 241 patients (23.6%) underwent 
stPLND with a node yield of 15.6. In Table 2 are shown pathologic data according to standard and 
extended procedures. 
In Table 3 are reported survival results stratified for stage, relaps and adjuvant treatment. 
75 patients (6.7%) presented disease persistence after surgery and are now alive and free of disease. 
Most of these patients (54) had a pT3 tumor; 17 a pT2 and just 4 a pT4. 536 patients (48.1%) had a 
biochemical recurrence followed by adjuvant therapy; 527 (98.3%) are still alive;  6 (1.1%) died due 
to the tumor and 3 (0.6%) for other causes. 500 patients (44.9%) didn’t receive any adjuvant 
treatment; most of them had a pT3 tumor (327), 155 had a pT2 and 18 a pT4. 472 (94.4%) are still 
alive; 14 (2.8%) died due to the tumor and 14 (2.8%) due to other causes. As reported in Table 4 age 
(P= 0.0006), pT (P< 0.0001), pN (P= 0.0018) and surgical margins (P= 0.0076) resulted as 
independent predictors for BR in multivariate analysis. 
Figures 1, 2, 3, 4 and 5 show survival curves with Kaplan-Meier model for DFS. Table 5 identifies 
pN (P=0.0025) and Gs (P= 0.0003) as independent predictors for OS and CSS in a univariate analysis; 
just the Gs results significant in the multivariate model. 
At a mean follow-up of 74 months 911 patients (81.8%) were continent. 
  
Pathological results 
In Table 6 are reported clinical stagings and our final pathological results. 237 patients were cT1; 64 
(27%) pT2 and 173 (73%) pT3. All the cT4 tumors were confirmed by final pathological examination. 
DISCUSSION 
Prostate cancer is characterized by heterogeneus presentation, extension and progression. The 
D’Amico classification allows a risk stratification helping the urologist to suggest the patient the best 
therapeutic opportunity. However it remains impossible to surely predict the behavior of the disease, 
its progression, treatment success and the risk of biochemical recurrence [9]. If it’s generally not easy 
to choose the best approach it is even more difficult when we have to face an high risk tumor [10]. 
The surgical approach remains nowadays a matter of debate; radical prostatectomy plays an important 
role and it still very controversial if a mininvasive technique should be the standard of care [4, 5, 11].  
The safety of the procedure and its feasibility is strongly related to the complications. Gontero et al 
described radical prostatectomy for high risk patients as an acceptable procedure in terms of 
morbidity; with increasing in surgery time, transfusion rate, and lymphoceles [12]. Recently Soares 
et al described a large population of 1138 patients treated with LRP [13]. More than 80% were  low-
intermediate risk patients according to D’Amico classification. The overall complication rate was 
5.2% (59 patients); which is lower than our 16.2% (180 patients); this group becomes significantly 
smaller if we exclude patients who needed  blood transfusions, remains than 54 patients (4.8%). 
Encouraging data emerge analyzing grade III complications; the author describes complication rate 
of 3.3%, higher than our 1.4%. Our results seems encouraging also compared with those presented 
by Di Benedetto et al: 446 patients with high risk tumor undergoing LRP; the author describes an 
overall complication rate of 7.6% and a grade III rate of 6.5% [14].  
Certainly we report a significant transfusion rate (11%); however this value is not so far from many 
results described in literature for LRP: Artibani et al describe a TR of 11% in a series of 71 patients, 
in a series of 219 patients the TR for Rassweiler et al is 9.6% and 9.8 % for Rozet et al after 133 LRP 
[15,16,17]. 
We can assume thatcomplications are relatively rare and most of them are not severe and also easy to 
treat.  
The mean (SD) overall lymph node yield was 18.5 (5.7) which is comparable to data described in 
literature for open and robotic surgery [18]. 
781 patients (76.4%) underwent ePLND with a node yield of 19.1; 241 patients (23.6%) underwent 
stPLND with a node yield of 15.6. In Table 2 are shown pathologic data according to standard and 
extended procedures. 
Our results are encouraging about the node yield if compared to literature; for an adeguate detection 
is described as necessary a node yield of at least 13 nodes removed during PLND of high risk PCa 
patients for robotic surgery by Sagalovich et al [19] and for retropubic prostatectomy by Briganti et 
al [20]. 
We obtained an overall survival of 96.6% (1076) and a disease free survival of 66.2% (737 patients) 
at a mean follow up of 74 ± 50 months which is acceptable if compared with results by Rassweiler et 
al. that described an OS of 94.9 % and a DFS fo 78.2 % in patients laparoscopically treated with 
organ confined tumors. Our OS and DFS are also comparable with those recently described by 
Borjian et al. [21] and Di Benedetto et al [14] for patients with high risk tumors treated with open and 
laparoscopic approach respectively. The last author presents a population of 446 patients and find out 
that the minimally invasive approach doesn’t hide worse oncological and functional outcome if 
compared with an open approach. Probably the most important comparison should be made against 
radiotherapy that is described by randomized studies as the best approach for these tumors; our results 
are encouraging and seem comparable to the serie presented by Bolla et al. of RT and 3 years of 
androgen deprivation therapy [22].  Table 3 shows how an adjuvant therapy plays a positive role in 
survival rate in proportion to the higher T stage. The disease persistence occurred in 75 patients after 
surgery; they all received an adjuvant treatment and 74 of them were alive with no BR at the follow 
up. 500 patients didn’t receive any adjuvant therapy after surgery; 438 of them result alive and free 
of disease at the follow up. We think our data we describe an encouraging outcome for patients 
recieveing adjuvant therapy; however it’s not easy to state the best timing like Zwergel et al try to do; 
they describe a 5 year PSA progression-free survival rate of 76% in patients with immediate hormonal 
treatment an of 53% in patients with surveillance and delayed hormonal therapy [23]. 
Our uni- and multivariate analysis show that pT and pN are directly proportional to the probability of 
BR. Positive surgical margins are also a positive predictor for BR. The age at the surgery is inversely 
proportional; younger patients are more likely to present BR after surgery. These correlations are well 
described in Kaplan-Mayer courves. On the contrary, in Zwergel’s analysis none of the investigated 
parameters was demonstrated to be of independent prognostic significance for tumor-specific survival 
but in an importantly smaller population. The data regarding pN confirms the importance of 
lymphadenectomy in these patients as described by Briganti et al. developing the well known 
nomogram and by Bader who analyzed the survival of patients with positive nodes [24,25]. Our data 
seems in line with the growing evidence that ePLND plays not only a prognostic role but also a 
therapeutic one in high risk patients, there is now level 1 evidence as reported in literature [26]. 
Just pN and pGS resulted as predictors for overall- and cancer specific survival; they are obviously 
inversely proportional. 
The comparison of clinical and pathological stage brought interesting results. We reported a clinical 
understaging in about 30% of cT2 and in 100% of cT1. That means that patients clinically considered 
as low or intermediate risk could reveal an high risk tumor, it plays a foundamental role in defining 
the disease and approach it with the best treatment.  
CONCLUSIONS 
Our work brings encouraging data about the oncological and functional safety of laparoscopic radical 
prostatectomy even in high-risk patients. We believe that radical prostatectomy represents an 
effective treatment for patients with high risk prostate cancer and that laparoscopy is a safe approach 
offering a mini-invasive alternative to open surgery. It permits also to a better identification and 
characterization of the disease leading to a more accurate evaluation of the prognosis and planning of 
the follow-up. We therefore propose a more comprehensive use of this technology in all patients who 
are candidates for surgery. 
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TABLES
Table 1: preoperative characteristics
General preoperative characteristics
Total population 1114
Mean Age (± SD; range) 62.0 ± 8 (32 – 79)
PSA
 ≥ 100 13 (1.2%)
50 – 99.9 64 (5.8 %)
20 – 49.9 299 (26.8 %)
10 – 19.9 280 (25.1 %)
< 10 458 (41.1 %)
cT
cT1b 2 (0.2 %)
cT1c 235 (21.2 %)
cT2a 101 (9.1 %)
cT2b 15 (1.3 %)
cT2c 218 (19.7 %)
cT3a 294 (26.5 %)
cT3b 196 (17.7 %)
T4 48 (4.3 %)
Gleason Score
10 23 (2.2 %)
9 99 (9.3 %)
8 304 (28.7 %)
7 371 (34.9 %)
≤ 6 264 (24.9 %)
Table 2: postoperative data
Post-operative data
pT
· pT2a
· pT2b
· pT2c
· pT3a
· pT3b
· pT4
21 (1.9%)
11 (1.0%)
264 (23.7%)
421 (37.8%)
348 (31.2%)
49 (4.4%)
pN
· pNx
· pN0
· pN1
· pN2
92 (8.3%)
904 (81.1%)
115 (10.3%)
3 (0.3%)
pGS
· 10
· 9
· 8
· 7
· ≤ 6
14 (1.3%)
199 (17.9%)
214 (19.2%)
504 (45.2%)
183 (16.4%)
Surgicalmargins
· Positive
· Negative
383 (34.4%)
731 (65.6%)
Continence at last follow-up
Continent patients
911 (81.8%)
Incontinent patients 203 (18.2%)
Follow-up
Follow-up (mean ± SD) 74 ± 50 months
Cancer related deaths 21 (1.9%)
Other causes deaths 17 (1.5%)
Alive with disease 339 (30.4%)
Alivewithout disease 737 (66.2%)
Grade Complications (treatment) N° of patients
I Anastomotic dehiscence (prolonged catheterisation)
Obturator nerve lesion (rehabilitation)
Haemorrhage, haematoma (no transfusion)
14 (1.3%)
1 (0.1%)
8 (0.7%)
Tot. = 23 (2.1%)
II Urinary tract infections; septicemia (antibiotics)
Haemorrhage (transfusions)
Rectal lesion (medical therapy and NGT)
Paralytic ileus (medical therapy and NGT)
Ileallesion (medical therapy and NGT)
3 (0.3%)
132 (11.8%)
5 (0.4%)
4 (0.4%)
1 (0.1%)
Tot. = 145
(13.0%)
III
IIIa
IIIb
Lymphocele, lymphorrhea (percutaneous drainage)
Rectal lesion (colostomy and recanalisation)
Rectal-bladder/urethral fistula (surgery)
Bladder-cutaneous fistula (surgery)
11 (1.0%)
1 (0.1%)
3 (0.3%)
1 (0.1%)
Tot. = 16 (1.4%)
IV
IVa
IVb
Transient ischemic attack
Iliac vein lesion
1 (0.1%)
1 (0.1%)
Tot. = 2 (0.2%)
V 0
Pathologic data for stPLND and ePLND
ePLND stPLND
N0 699 (89.5%) 217 (90%)
N1 80 (10.2%) 23 (9.5%)
N2 2 (0.3%) 1 (0.4%)
Tot. 781 241
Table 3: survival data
pT * Relapse * Adjuvant therapy* Follow-up *
pT2 (296)
Relapse (126)
(42.6%)
No adjuvant therapy (2)
(1.6%)
Alive with disease (2)
(100%)
Adjuvant therapy (124)
(98.4%)
Cancer deaths (2)
(1.6%)
Alive with disease (38)
(30.7%)
Alive without disease (84)
(67.7%)
No relapse **(170)
(57.4%)
No adjuvant therapy (153)
(90.0%)
Other causes deaths
(3) (2.0%)
Alive without disease (150)
(98.0%)
Adjuvant therapy (17)
(10.0%)
Alive without disease (17)
(100%)
pT3 (766)
Relapse (438)
(57.2%)
No adjuvant therapy (53)
(12.1%)
Cancer deaths (10)
(18.9%)
Other causes deaths
(1) (1.9%)
Alive with disease (32)
(60.3%)
Alive without disease (10)
(18.9%)
Adjuvant therapy (385)
(87.9%)
Cancer deaths (4)
(1.0%)
Other causes deaths
(3) (0.8%)
Alive with disease (237)
(61.6%)
Alive without disease (141)
(36.6%)
No relapse ** (328)
(42.8%)
No adjuvant therapy (274)
(83.5%)
Cancer deaths (3)
(1.1%)
Other causes deaths
(10) (3.6%)
Alive without disease (261)
(95.3%)
Adjuvant therapy (54)
(16.5%)
Alive with disease (1)
(1.9%)
Alive without disease (53)
(98.1%)
pT4 (49)
Relapse (27)
(55.1%)
No adjuvant therapy (0)
Adjuvant therapy (27)
(100%)
Alive with disease (22)
(81.5%)
Alive without disease (5)
(18.5%)
No relapse ** (22)
(44.9%)
No adjuvant therapy (18)
(81.8%)
Cancer deaths (1)
(5.6%)
Alive without disease (17)
(94.4%)
Adjuvant therapy (4)
(18.2%)
Alive without disease (4)
(100%)
* (n° pz)
** Patients with biochemical recurrence and patients with persistent diesease after surgery
Table 4: predictors for BR
Univariate analysis Multivariate analysis
Age at HR (CI 95%) < .0001
prostatectomy 0.98 (0.97 – 0.99)
Age at HR (CI 95%) 0.0005
Prostatectomy 0.98 (0.97 – 0.99)
pT HR (CI 95%) < .0001
T2* 1
T3 1.8 (1.5 – 2.3)
T4 2.4 (1.6 – 3.4)
pT HR (CI 95%) < .0001
T2* 1
T3 1.7 (1.4 – 2.1)
T4 2.2 (1.5 – 3.2)
pN HR (CI 95%) < .0001
N0* 1
N1 + N2 1.7 (1.4 – 2.2)
Nx 1.2 (0.9 – 1.5)
pN HR (CI 95%) 0.0011
N0* 1
N1 + N2 1.6 (1.2 – 2.0)
Nx 1.2 (0.9 – 1.5)
Surgical margins HR (CI 95%) < .0001
Negative* 1
Positive 1.4 (1.2 – 1.6)
Surgical margins HR (CI 95%) 0.0083
Negative* 1
Positive 1.2 (1.1 – 1.5)
pGS HR (CI 95%) 0.0465
7* 1
≤ 6 1.2 (1.0 – 1.5)
8 1.3 (1.1 – 1.6)
9 1.3 (1.0 – 1.6)
10 1.1 (0.5 – 2.1)
Lymphadenectomy HR (CI 95%) 0.4061
0.9 (0.7 – 1.2)
PSA pre HR (CI 95%) 0.0230
1.004 (1.000 – 1.007)
*Reference category
Table 5: predictors for OS and CSS
Univariate analysis
pT HR (CI 95%) 0.4836
T2* 1
T3 2.5 (0.7 – 15.7)
T4 2.4 (0.3 – 20.6)
pN HR (CI 95%) 0.0025
N0* 1
N1 + N2 5.6 (1.9 – 14.5)
Nx 1.2 (0.3 – 3.9)
§pGS HR (CI 95%) 0.0003
≤ 6* 1
7 2.0 (0.3 – 40.8)
8 9.0 (1.4 – 172.9)
9 22.5 (4.3 – 411.4)
10 26.3 (1.0 – 668.4)
Surgical margins HR (CI 95%) 0.7715
Negative* 1
Positive 0.9 (0.4 – 2.1)
PSA pre HR (CI 95%) 0.3764
0.99 (0.95 – 1.01)
*Reference category
§pGS was the only variable that maintained statistical significance at multivariate analysis.
Table 6: conrespondance between clinical and pathological stage
Clinical stage Pathological stage
cT1 (237)
· cT1b (2)
· cT1c (235)
pT2 (64); pT3 (173)
· pT3a (1); pT3b (1)
· pT2a (10); pT2b (5); pT2c (49); pT3a (97); pT3b (74)
cT2 (334)
· cT2a (101)
· cT2b (15)
· cT2c (218)
pT2 (227); pT3 (107)
· pT2a (9); pT2b (1); pT2c (20); pT3a (38); pT3b (33)
· pT2b (4); pT2c (2); pT3a (3); pT3b (6)
· pT2a (1); pT2b (1); pT2c (189); pT3a (14); pT3b (13)
cT3 (490)
· cT3a (294)
· cT3b (196)
pT2 (5); pT3 (484); pT4 (1)
· pT2a (1); pT2c (4); pT3a (263); pT3b (25); pT4 (1)
· pT3a (1); pT3b (195)
cT4 (48) pT4 (48)
